Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.